ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. - Wikidata - awgldk - TriplyDB

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

http://www.wikidata.org/entity/Q42225140

about

Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysis Pharmacological treatments for acute hepatitis C infection: a network meta-analysis Management of HCV-Associated Liver Cirrhosis.Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C Pleiotropic effects of statins in the diseases of the liver Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review Recent Advances in Antiviral Therapy for Chronic Hepatitis C Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease KASL clinical practice guidelines: management of hepatitis C Treating hepatitis C - what's new?Advances in hepatitis C therapy: What is the current state - what come's next?New approaches in the treatment of hepatitis C Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Chronic hepatitis C: This and the new era of treatment Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes Era of direct acting antivirals in chronic hepatitis C: Who will benefit?The New Era of Interferon-Free Treatment of Chronic Hepatitis C Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies Impact of new treatment options for hepatitis C virus infection in liver transplantation The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?Hepatitis C cirrhosis: New perspectives for diagnosis and treatment New era for management of chronic hepatitis C virus using direct antiviral agents: A review Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in Hepatitis C virus-HIV-coinfected patients and liver transplantation Antiviral therapies for chronic hepatitis C virus infection with cirrhosis Hepatitis C virus: Promising discoveries and new treatments Targeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver Fibrosis Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis Anti-hepatitis C virus drugs and kidney Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

P2860

Q24186846-27DCF51B-799E-4F46-AC55-88D0CBCFCA1B Q24186859-8ECA2E0B-B2E0-4687-964B-83E0582B70B3 Q26740320-675B0045-12F3-419F-B32B-4367A9AAC769 Q26741123-6B81237F-5012-4A0A-8A03-8E21FEF0C8C5 Q26741176-3F6C6A4E-EC43-40E7-BF66-2013E2B0A404 Q26746563-79FDD8A6-A78C-4D38-9D10-688573CC8D81 Q26747705-CD5AD9B5-773D-4F6B-8E8E-86E3EA54500F Q26750476-5B6135E4-5591-4298-8A63-52362F7D3A69 Q26751452-5C5F024B-39AC-4D85-A57F-6D41581B2453 Q26752433-1463245C-078A-458B-BDE9-2092EAF7B90E Q26752471-03773411-211E-4D3C-AE08-39ABDE932F4C Q26769646-CF1FDACB-6D36-482D-A020-2B57FA8122FD Q26770036-2808D6BE-CD86-4200-AEC6-7E958C581C0B Q26773271-659E8D74-461C-498D-8731-88A214FA89A3 Q26773585-2FE2F0BB-9FDD-4F7E-94B9-5A1D22FFEEF9 Q26775011-15913795-05A6-4B70-A615-2154BE839A98 Q26775825-DBF4D0C4-CFAA-4FAD-B40F-A09C1404A7F9 Q26777086-5D2D745F-1F2A-4E3D-9738-3728DF383675 Q26777506-F1F16F4D-3DAE-4B84-A939-F5F609FC9A44 Q26777716-964C9A29-8CD4-473A-866B-B98C09F19438 Q26781331-419B2278-D626-4C1F-B719-A9A862949D6B Q26781770-4583C028-7A87-4E7E-9FBD-5659D5D06ECF Q26781890-93A0D70C-000C-4E00-AA61-C57B518B99A2 Q26782009-F6CC346F-F9DA-4148-A69E-0A24B78AC658 Q26782017-D2A2A800-0905-4A69-86D4-EF79C5D607AD Q26795559-C568805F-297C-497D-8C21-1575997681F9 Q26798469-E7B82834-7A65-4E3D-81AE-3E00160CE443 Q26799924-8C10DE7A-0B41-4B7B-9A0C-99BE2003D087 Q26800050-74A6128D-A4C2-42B0-894E-349BF5128364 Q26801423-EE44B544-830D-4122-9E0A-EB1AA52CF658 Q26801828-A98DF169-BD0E-41ED-BD80-42D30361083B Q26820811-B50A4854-3E8C-471C-A7F4-EDF86E124993 Q27011255-F1511811-5A41-4008-ABD6-43FA87BD734E Q27022794-E923BC0F-ED71-4178-966C-AD7FF54EA19B Q27468916-66A4B5CE-C9AB-4C81-92D2-2585BD714737 Q28070012-872ECC8A-138D-4117-88AC-8CDB9F2E798D Q28070260-9181D432-690E-4F1A-A569-F897CA94F850 Q28070279-A6581011-6980-431D-A0AA-045AD893FC51 Q28075544-827A7EA5-7D8C-48F5-9735-1DE27B9091EB Q28079102-55F1DFC8-8DA5-4E67-8785-A362C2E9D5E1

P2860

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

http://www.wikidata.org/entity/Q42225140

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@en

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@nl

type

label

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@en

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@nl

prefLabel

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@en

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@nl

P1433

Q42225140-DAD8A4F0-EAD6-4C88-AF3E-40BBE4360F6E

P1476

Q42225140-36E62171-6C43-4017-932C-69F6EE37BC2C

P2093

Q42225140-03589454-CB8B-4E46-8446-950A795D37C5

Q42225140-07509100-48C1-486D-AF9D-DEE4E33DA6B1

Q42225140-3A5CC42C-0786-42B5-9C10-4BBA25EE4376

Q42225140-45A92CAC-85A5-42A6-8F3E-E35548B71E03

Q42225140-48283147-20FD-4FD8-AED8-2A160F7D6675

Q42225140-51DE257A-59B9-4228-BE48-A8405D19AD05

Q42225140-566D765E-E086-43F1-A2D7-DF0E51B65A04

Q42225140-6ADEF943-734A-4998-B8C8-BC4A1E8F460A

Q42225140-6C0E1D53-1B36-4C50-ABEF-B9B1800E0F1D

Q42225140-86D43E43-496A-468E-80DF-07D73308FA54

P304

Q42225140-F3AE6AD0-AE81-46A8-9E7C-72BF9C3DADEC

P31

Q42225140-16369486-C5D3-4FF5-8DF7-052146AE293E

P356

Q42225140-128C4FB8-EC06-4D4A-A0A1-6FA4DF87504E

P407

Q42225140-41FD5637-3946-419E-B8C5-53CC0AD861AE

P433

Q42225140-C75BB972-5380-4D51-BC1A-15ED155E489A

P478

Q42225140-99BAFD2D-EA91-4F3B-A7ED-677DA03E4CF4

P50

Q42225140-4811DE22-E8E3-47B0-92B0-7A02148386DB

Q42225140-72B533E9-45FE-4965-A98E-6BE97DD89822

Q42225140-8F58D7A7-87EE-4FBB-9225-BE33281CD96E

P577

Q42225140-A2B87170-5100-435B-9A37-91AD05045579

P698

Q42225140-272C9508-58B0-404E-B006-2553CFE4A5D4

P921

Q42225140-5A8A17D5-949B-44B0-9681-EECA4888FBF1

Q42225140-EE863AC5-6670-42FE-9EE0-2070CEFAE778

P356

P1433

The New England Journal of Medicine

P1476

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

@en

P2093

Andrew L Campbell

http://www.w3.org/2001/XMLSchema#string

Barbara Da Silva-Tillmann

http://www.w3.org/2001/XMLSchema#string

Barry Bernstein

http://www.w3.org/2001/XMLSchema#string

Christine A Collins

http://www.w3.org/2001/XMLSchema#string

Christophe Hezode

http://www.w3.org/2001/XMLSchema#string

Eric M Yoshida

http://www.w3.org/2001/XMLSchema#string

Heiner Wedemeyer

http://www.w3.org/2001/XMLSchema#string

Kosh Agarwal

http://www.w3.org/2001/XMLSchema#string

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

P304

1973-1982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1402869

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24725237

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis